Zimbabwe has rejected a major American health deal valued at $367m (£272m) over five years because of Washington's demand for confidential biological samples.
This move came to light after a government memo dated December was disclosed, indicating that President Emmerson Mnangagwa deemed the deal was "unbalanced".
An official representative later explained that the US was requesting biological samples for research and commercial gain but was unwilling to guarantee the benefits from future medical innovations.
"We will now turn to the difficult and regrettable process of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had provided over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for continued dialogue to secure a deal acceptable to both sides so the nation's vital HIV programme can be sustained.
Broader Context
This rejection comes after a comparable case in Kenya, where a court blocked a related deal with the US following concerns were raised about the security of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had managed assistance for the American government, but Trump stated its expenditure was "wasteful" and his government was seeking direct bilateral agreements to boost transparency and responsibility.
Based on reports, 16 nations in Africa have to date agreed to similar agreements, representing over $18.3bn in committed funds.
Details of the Declined Agreement
This assistance for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving antiretroviral therapy through US-supported programmes," Tremont said.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to share its genetic material and health information indefinitely, without any corresponding promise of access to any scientific breakthroughs – like new medicines or tests – that might be developed from that provided information," Mangwana explained.
"Effectively, our nation would supply the basic resources for medical research without any certainty that the end products would be accessible to our people if a new health crisis emerge."
National Interest and International Frameworks
Mangwana further said that the American exit from the global health body and its pursuit of bilateral health agreements were undermining structures previously established via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to deal with future pandemics.
"This mechanism is intended to guarantee that when a country provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to create them."
These objections over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage ongoing discussions with our American counterparts on how subsequent co-operation might be arranged in a way that respects the independence and dignity of each country."
Medical Community Response
Medical experts stated it understood the official position, but urged that talks must proceed considering a large portion of the nation's Aids initiatives were funded by external financing.
"Where specific concerns arise, such as those involving data governance or implementation frameworks, these can often be resolved via technical clarification and negotiated safeguards," it commented.
This impasse underscores the continuing debate between receiving crucial international aid and safeguarding local interests in an ever more interconnected world.